CND Life Sciences Inc. has raised $13.5 million in its Series A equity financing round, with $8.6 million in its most recent Series A3 offering. The company’s strong growth has been fueled by its Syn-One Test that uses skin biopsy tissue to detect and quantify the abnormal form of the alpha-synuclein protein, a known pathological hallmark of Parkinson’s disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy and other related disorders. “This is a defining tim...